


Form PTO-1595 (Rev. 10/02) OMB No. 0651-0027 (exp. 6/30/2005) Tab settings ⇌ ⇌ ⇌ ▼ ▼ ▼ ▼ ▼ ▼ ▼		RECORDATION FORM COVER SHEET PATENTS ONLY		U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office	
To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.					
1. Name of conveying party(ies): ADViSYS Inc. 2700 Research Forest Drive, Ste 180 The Woodlands, TX 77381 Additional name(s) of conveying party(ies) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No			2. Name and address of receiving party(ies) Name: Estate of Gordan A. Cain Internal Address: c/o James D. Weaver, Executor Street Address: 8 Greenway Plaza, Suite 792 City: Houston State: TX Zip: 77046 Additional name(s) & address(es) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		
3. Nature of conveyance: <input type="checkbox"/> Assignment <input type="checkbox"/> Merger <input checked="" type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name <input type="checkbox"/> Other _____ Execution Date: 12/22/2003					
4. Application number(s) or patent number(s): If this document is being filed together with a new application, the execution date of the application is: _____ A. Patent Application No.(s) see attached B. Patent No.(s) see attached Additional numbers attached? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No					
5. Name and address of party to whom correspondence concerning document should be mailed: Name: James D. Weaver, Executor Internal Address: Suite 792 Street Address: 8 Greenway Plaza City: Houston State: TX Zip: 77046			6. Total number of applications and patents involved: 27 7. Total fee (37 CFR 3.41).....\$ 1080.00 <input type="checkbox"/> Enclosed <input checked="" type="checkbox"/> Authorized to be charged to deposit account 8. Deposit account number: 22-0365 Attn: APP805/29000		
DO NOT USE THIS SPACE					
9. Signature. David Wooten Name of Person Signing  Signature 1/14/04 Date Total number of pages including cover sheet, attachments, and documents: 19					

Mail documents to be recorded with required cover sheet information to:
Commissioner of Patents & Trademarks, Box Assignments
Washington, D.C. 20231

CH \$1080.00 220365 10315907

Continuation of Item 4

A.	Patent Application Numbers:	B.	Patent Number:
	10/315,907		
	PCT/US02/39509		6,551,996
	10/021,403		
	PCT/US01/48726		
	60/362,362		
	10/360,768		
	10/657,725		
	PCT/US03/06833		
	10/166,356		
	10/262,141		
	10/262,377		
	PCT/US03/25975		
	10/359,919		
	PCT/US03/03640		
	10/395,709		
	PCT/US03/16541		
	10/619,939		
	PCT/US03/21917		
	10/166,356		
	60/423,536		
	60/474,749		
	60/443,104		
	60/454,079		
	60/457,214		
	60/464,266		
	60/492,427		

SECURITY AGREEMENT

THIS SECURITY AGREEMENT, made and entered into as of December 22, 2003, by and between ADViSYS, Inc., a Delaware corporation ("Debtor"), and the Estate of Gordon A. Cain (the "Estate"), William A. McMinn ("McMinn"), an individual residing in Houston, Texas and Baylor College of Medicine ("Baylor" and collectively with the Estate and McMinn, the "Secured Parties"), a Texas nonprofit corporation having its principal place of business in Houston, Texas.

WITNESSETH:

WHEREAS, Debtor has issued separate Secured Promissory Notes of even date herewith to each of the Secured Parties; and

WHEREAS, to secure Debtor's payment of all amounts owed pursuant to each of the Secured Promissory Notes, Debtor now wishes to grant each of the Secured Parties a security interest in and lien on the "Collateral" as defined herein;

NOW THEREFORE in consideration of the foregoing Debtor agrees to provide security for the performance of its obligations under the Agreement as follows:

1. Defined Terms. The following terms which are defined in the Uniform Commercial Code in effect in the State of Texas on the date hereof are used herein as so defined: Payment Intangibles, Electronic Chattel Paper, Investment Property, Supporting Obligations, Deposit Accounts, Letter-of-Credit Rights, Commercial Tort Claims; and the following terms shall have the following meanings:

"Account Debtor": A person obligated on an Account, Chattel Paper, or General Intangible.

"Patents": (a) All letters patent of the United States and all reissues and extensions thereof, including, without limitation, any thereof referred to in Schedule I hereto, and (b) all applications for letters patent of the United States and all divisions, continuations and continuations-in-part thereof or any other country, including, without limitation, any thereof referred to in Schedule I hereto.

"Patent License": All agreements, whether written or oral, providing for the grant by either Grantor of the right to manufacture, use or sell any invention covered by a Patent, including, without limitation, any thereof referred to in Schedule I hereto.

"Trademarks": (a) All trademarks, trade names, corporate names, company names, business names, fictitious business names, trade styles, service marks, logos and other source or business identifiers, and the goodwill associated therewith, now existing or hereafter adopted or acquired, all registrations and recordings thereof, and all applications in connection therewith, whether in the

United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country or any political subdivision thereof, or otherwise, including, without limitation, any thereof referred to in Schedule II hereto, and (b) all renewals thereof.

“Trademark License”: Any agreement, written or oral, providing for the grant by either Grantor of any right to use any Trademark, including, without limitation, any thereof referred to in Schedule II hereto.

“UCC”: The Uniform Commercial Code as from time to time in effect in the State of Texas.

2. **Grant of Security Interest.** Debtor hereby grants to each of the Secured Parties, its successors and assigns, a continuing security interest in all of Debtor’s right, title and interest in and to the following, in each case whether now or hereafter existing or in which Debtor now has or hereafter acquires an interest and wherever located (hereinafter collectively called the “Collateral”):

- (a) All accounts;
- (b) All Chattel Paper (including, without limitation, all Electronic Chattel Paper and all Tangible Chattel Paper);
- (c) All documents (including without limitation, all laboratory records);
- (d) All equipment, furniture and other personal property
- (e) All General Intangibles (including, without limitation, all Payment Intangibles);
- (f) All instruments;
- (g) All inventory including biological samples and animals;
- (h) All Investment Property
- (i) All Patents;
- (j) All Patent Licenses;
- (k) All Trademarks;
- (l) All Trademark Licenses;
- (m) All vehicles;
- (n) All Deposit Accounts;
- (o) All Letter-of-Credit Rights;
- (p) All Commercial Tort Claims;
- (q) All Supporting Obligations that support the payment or performance of an Account Chattel Paper, a Document, a General Intangible, an Instrument or Investment Property; and
- (r) All proceeds and products of any of the foregoing.

3. **Security for Obligations.** This Agreement secures, and the Collateral assigned by Debtor is collateral security for, the following obligations of Debtor (hereinafter collectively called the “Obligations”):

- (a) the full and prompt performance by Debtor of each of its obligations under each of the Secured Promissory Notes, including without limitation, the payment of all amounts owed thereunder; and

(b) any and all covenants, agreements, liabilities and obligations of Debtor to the Secured Parties, its successors and assigns provided for or arising under this Security Agreement.

4. Debtor Representations, Warranties and Covenants. Debtor hereby represents, warrants and covenants to each of the Secured Parties as follows:

(a) Unless one of the Secured Parties agrees otherwise, in writing, all Collateral will be kept at its current location at all times;

(b) Debtor is and will be at all times the owner of the Collateral, and no person other than the Secured Parties has any security interest or lien upon any of the Collateral;

(c) Debtor intends that the security interest in the Collateral granted to the Secured Parties hereunder shall constitute a valid security interest in the Collateral, securing performance of the Obligations and Debtor agrees not to take a position to the contrary in the future. Upon Secured Parties filing of UCC financing statements naming Debtor as "debtor", naming the Secured Parties as "the Secured Parties" and describing the Collateral with the Secretary of State in Debtor's state of incorporation, Debtor and the Secured Parties intend to perfect the security interest in the Collateral granted to the Secured Parties which security interest is intended to be prior in interest to all other liens;

(d) Except for any financing statements to be filed pursuant to this Security Agreement and any other financing statements running for the benefit of the Secured Parties, no financing statement or other acknowledgment of lien covering any Collateral is on file in any public office. Debtor shall, at Debtor's cost and upon the request of any of the Secured Parties, execute and deliver to the Secured Parties such financing statements, assignments, and other documents in form satisfactory to the Secured Parties, and do all such further acts and things as any of the Secured Parties may at any time and from time to time reasonably request or as may be necessary or appropriate to establish and maintain a valid perfected security interest in the Collateral as security for the Obligations; provided, however, that Debtor shall not be required to make any payments to any person or otherwise incur any out-of-pocket costs in satisfying the foregoing obligation costs that are not commercially reasonable. Without limiting the generality of the foregoing, Debtor will: (i) execute such financing or continuation statements, or amendments thereto, and (ii) deliver such other instruments or notices, in each case, as may be necessary or desirable, or as any of the Secured Parties may reasonably request, in order to perfect and preserve the security interests granted or purported to be granted hereby; provided, however, that Debtor shall not be required to take any action hereunder if such action would be materially detrimental to it. Debtor and the Secured Parties agree that the execution of this Security Agreement and the performance by Debtor of its obligations hereunder shall not be deemed to be materially detrimental to Debtor. Debtor hereby authorizes each of the Secured Parties to file one or more financing or continuation statements, and amendments thereto, relative to all or any part of the Collateral. Debtor agrees that a carbon, photographic or other reproduction of this Agreement or of a financing statement signed by Debtor shall be sufficient as a financing statement and may be filed as a financing statement in any and all jurisdictions. The Secured Parties shall be solely responsible for and will pay the cost of filing or recording the

same or filing or recording this Security Agreement in all public offices wherever filing or recording is deemed by the Secured Parties to be necessary or desirable;

(e) Debtor will notify each of the Secured Parties of any change in Debtor's name within 15 days of such change;

(f) Debtor will notify each of the Secured Parties of any change of the jurisdiction of organization of Debtor within 15 days of such change; and

(g) Debtor will not sell, assign, pledge, lease or otherwise transfer or encumber the Collateral, or any interest therein, without the prior written consent of one of the Secured Parties, which shall not be unreasonably withheld, conditioned or delayed.

5. Default. The occurrence of any of the following events or conditions shall constitute an immediate "Default" under this Security Agreement:

(a) A default by Debtor under any of the Secured Promissory Notes; or

(b) A default in the performance by Debtor or attributable to Debtor of any of the other Obligations or of any other covenants, agreements, or obligations contained or referred to herein if not cured within thirty (30) days after written notice from any of the Secured Parties.

6. Standard of Care. The powers conferred on each of the Secured Parties hereunder are solely to protect its interest in the Collateral and shall not impose any duty upon it to exercise any such powers. Except for the exercise of reasonable care in the custody of any Collateral in its possession and the accounting for moneys actually received by it hereunder, each of the Secured Parties shall have no duty as to any Collateral or as to the taking of any necessary steps to preserve rights against prior parties or any other rights pertaining to any Collateral. Each of the Secured Parties shall be deemed to have exercised reasonable care in the custody and preservation of Collateral in its possession if such Collateral is accorded treatment substantially equal to that which the Secured Party accords its own property.

7. Rights Upon Default. If a Default shall occur hereunder and be continuing at any time thereafter each of the Secured Parties shall have the right, individually, to take any action with respect to or to enforce any rights granted hereunder, or by law, with respect to the security interest and the Collateral and each of the Secured Parties shall have, individually, all the remedies of a secured party under the Uniform Commercial Code as enacted in the State of Texas or, if the Default involves the Property, in any other jurisdiction in which the Property is located, and all other rights and remedies now or hereafter provided or permitted by law. Without limitation of the foregoing, upon such Default, each of the Secured Parties shall be entitled, individually, to hold, maintain and preserve all of the Collateral for sale and to dispose of the Collateral. Debtor will execute and deliver to each of the Secured Parties any and all forms, documents, certificates and registrations as may be necessary or appropriate to enable any of the Secured Parties, individually, to sell and deliver good and clear title to the Collateral to the buyer at the sale as herein provided. Each Secured Party will be entitled to a share of the net proceeds realized upon any disposition of the Collateral in proportion to the relative amounts owed under its or his Secured Promissory Note.

8. No Waiver. No waiver by any party of any Default hereunder shall operate as a waiver of any other Default or of the same Default on a future occasion. The remedies hereunder are cumulative and the exercise of any one or more of the remedies provided for herein, under the Uniform Commercial Code or otherwise, shall not be construed as a waiver of any other remedies so long as the Secured Promissory Notes, this Security Agreement or any part of the Obligations remain in effect.

9. Successors and Assigns. All rights of each of the Secured Parties hereunder shall inure to the benefit of its successors and assigns; and all obligations of each party hereunder shall bind its respective successors and assigns.

10. Invalidity. Each provision of this Security Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Security Agreement shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Security Agreement.

11. Individual Rights. Notwithstanding anything herein to the contrary, each of the Secured Parties may individually exercise any of the rights and powers granted herein to the Secured Parties without any consent or other approval from the other Secured Parties.

12. UCC Terms. The terms and provisions contained herein shall, unless the context otherwise requires, have the meanings and be construed as provided in the Uniform Commercial Code of the State of Texas.

13. Governing Law. Without limitation of the foregoing, this Security Agreement shall be governed by, and construed in accordance with, the laws of the State of Texas, without reference to its choice of law principles.

14. Notices. All notices, demands and requests given or required to be given hereunder shall be in writing. All such notices, demands and requests by either party to the other party shall be deemed to have been properly given if served in person or if sent by United States registered or certified mail, postage prepaid, or by overnight delivery by a nationally recognized overnight delivery service, addressed as follows:

If to the Secured Parties: Estate of Gordon A. Cain
James D. Weaver, Executor
The Sterling Group
8 Greenway Plaza
Houston Texas 77046

William A. McMinn
The Sterling Group
8 Greenway Plaza, Suite 702
Houston, Texas 77046
Facsimile: (713) 877-1824

With copies to: BCM Technologies
Attn: Christine Powaser
1709 Dryden, Suite 901
Houston, Texas 77030
Facsimile No.: (713) 795-4602

If to Debtor: ADViSYS, Inc.
Attn: President
2700 Research Forest Drive, Suite 180
The Woodlands, Texas 77381
Facsimile No.: (281) 296-1688


or to such other address as the party to be addressed may from time to time designate by written notice to the other party given as herein required. All notices, demands and requests shall be effective upon receipt.

15. Amendments, etc. No amendment, modification, termination or waiver of any provision of this Agreement, and no consent to any departure by Debtor therefrom, shall in any event be effective unless the same shall be in writing and signed by each of the Secured Parties and, in the case of any such amendment or modification, by Debtor. Any such waiver or consent shall be effective only in the specific instance and for the specific purpose for which it was given.

IN WITNESS WHEREOF, this Security Agreement has been executed as of the day and year first above written.


DEBTOR:

ADViSYS, Inc.,
a Delaware corporation

By: 
Name: Douglas R. Kohn
Title: President/CEO

THE SECURED PARTIES:

Estate of Gordon A. Cain

By: 
Name: James D. Weaver, Executor

William A. McMinn

By: _____
Name: William A. McMinn

Baylor College of Medicine

By: _____
Print Name: _____
Title: _____

IN WITNESS WHEREOF, this Security Agreement has been executed as of the day and year first above written.

DEBTOR:

ADViSYS, Inc.,
a Delaware corporation

By: *Douglas R. Kern*
Name: *Douglas R. Kern*
Title: *President / CEO*

THE SECURED PARTIES:

Estate of Gordon A. Cain

By: _____
Name: James D. Weaver, Executor

William A. McMinn

By: *William A. McMinn*
Name: William A. McMinn

Baylor College of Medicine

By: _____
Print Name: _____
Title: _____

IN WITNESS WHEREOF, this Security Agreement has been executed as of the day and year first above written.

DEBTOR:

ADViSYS, Inc.,
a Delaware corporation

By: Douglas R. Kean
Name: Douglas R. Kean
Title: President/CEO

THE SECURED PARTIES:

Estate of Gordon A. Cain

By: _____
Name: James D. Weaver, Executor

William A. McMinn

By: _____
Name: William A. McMinn

Baylor College of Medicine

By: William D Walker
Print Name: William D Walker
Title: Vice President

SCHEDULE I TO SECURITY AGREEMENT

Patents and Patent Licenses

ADDENDUM TO UCC FINANCING STATEMENT
DEBTOR: ADVISYS, INC.

AVSI	Title	Country	Patent or Patent Application No.	Filing Date
0005	Linear DNA Fragments for Gene Expression	United States	SN# 10/237,146 SN# PCT/US02/28508	09/06/02 09/06/02
0007	Plasmid Mediated Treatment for Anemia, Wasting, Immune Dysfunction and Life Extension for the Chronically Ill	United States	SN# 10/315,907 SN# PCT/US02/39509	12/10/02 12/10/02
		Argentina	SN# P020104785	12/10/02
		Chile	SN# 2829/2002	12/10/02
		Malaysia	SN# PI 20024609	12/10/02
		Thailand	SN# 078731	12/11/02
		Taiwan	SN# 91135752	12/10/02
0008	Body Mass, Decrease Body Fat Proportion, Increase Bone Density, and Improve Bone Healing Rate –(Provisional_ and a Composition and Method to Alter Lean Body Mass and Bone Properties in a Subject – (Utility)	United States	SN# 10/281,067 SN# PCT/US02/34275	10/25/02 10/25/02
0006		Chile	SN# 2446/2002	10/25/02
		Argentina	SN# P020104067	10/25/02
		Thailand	SN# 077598	10/25/03
		Malaysia	SN# PI20024000	10/25/02
		Taiwan	SN# 91125328	10/25/02

Schedule I - 1

PATENT

REEL: 014250 FRAME: 0990

ADDENDUM TO UCC FINANCING STATEMENT
DEBTOR: ADVISYS, INC.

AVSI	Title	Country	Patent or Patent Application No.	Filing Date
0009	Administration of Nucleic Acid Sequence to Female Animal to Enhance Growth in Offspring	United States	SN# 10/021,403	12/12/01
		Argentina	SN# P010105745	12/11/01
		Chile	SN# 3008/01	12/10/01
		Malaysia	SN# P120015621	12/11/01
		Thailand	SN# 070197	12/06/01
		Taiwan	SN# 90130829	12/12/01
		United States	SN# PCT/US01/48726	12/12/01
		Australia	SN# 2002248194	12/12/01
		Brazil	SN# P10116472-4	12/12/01
		Canada	SN# 2,430,921	12/12/01
		China	SN# (not yet received)	12/12/01
		Europe (EPC)	SN# 01997073.0	12/12/01
		Indonesia	SN# W00200301307	12/12/01
		Mexico	SN# _____	12/12/01
		New Zealand	SN# 526621	12/12/01
		Philippines	SN# 1-2003-500503	12/12/01
		Poland	SN# (not yet received)	12/12/01
		Singapore	SN# 200303372-7	12/12/01
		South Korea	SN# 10-2003-7007872	12/12/01
0010	Constant Current Electrode Assembly for Electroporation	United States	SN# 60/362,362	03/07/02
			SN# 10/360,768	03/07/02
			SN# 10/657,725	09/08/03
			SN# PCT/US03/06833	03/06/03
		Argentina	SN# P030100756	03/06/03
		Chile	SN#0447/2003	03/07/03

Schedule 1 - 2

ADDENDUM TO UCC FINANCING STATEMENT
DEBTOR: ADVISYS, INC.

AVSI	Title	Country	Patent or Patent Application No.	Filing Date
0011	Growth Hormone Release Hormone Expression System and Methods of Use, Including Use in Animals	Malaysia	SN# PI 20030786	03/06/03
		Taiwan	SN# 92104867	03/06/03
		Thailand	SN# 080694	03/06/03
		United States	Patent No. 6,423,693	07/24/98
0012	Method for the Identification of Synthetic Cell- Or-Tissue-Specific Transcriptional Regulatory Regions	Continued Application	SN# (not yet received)	04/16/02
		Australia (DIV)	SN# 2002300550	07/24/03
		Canada	SN# 2,297,375	
		Japan	SN# 2000-504270	
0013	Myogenic Vector Systems	Europe	SN# 108328.12	
		United States	Patent No. 6,410,228	07/14/98
		Continuation Application	SN# Not yet received	05/01/02
		PCT Application	SN# US98/14901	07/14/98
0013	Myogenic Vector Systems	Canada	SN# 2,296,771	
		Europe	SN# 98936904.6	
		Japan	SN# 2000-502228	
		Australia (Div)	SN# Unknown	
0013	Myogenic Vector Systems	United States	Patent No. 5,298,422	11/06/91
			Patent No. 5,756,264	03/09/94
			Patent No. 5,925,564	06/07/95
			SN#08/472,809	
0013	Myogenic Vector Systems	Australia	SN# 31246/93	11/03/92

ADDENDUM TO UCC FINANCING STATEMENT
DEBTOR: ADVISYS, INC.

AVSI	Title	Country	Patent or Patent Application No.	Filing Date
0014	Progesterone Receptor Having C. Terminal Hormone Binding Truncations/Mutated Steroid Hormone Receptors, Methods for their Use and Molecular Switch for Gene Therapy	United States	Patent No. 5,364,791 SN# 07/939,246 SN# 08/479,846 SN# 08/454,418	05/14/92 09/02/92 06/06/95 05/30/95
0015	Formulated Nucleic Acid Compositions and Methods of Administering the Same for Gene Therapy	United States	Patent No. 6,040,295	01/13/95
0017	Super Porcine Growth Hormone Releasing Hormone Analog	United States	Patent No. 6,551,996 SN# 10/166,356 SN# 10/262,141 SN# 10/262,377 SN# P030103014 SN# 1685/2003 SN# PI 20033155 SN# PCT/US03/25975 SN# 084574 SN# 92122793 SN# 66078/00 SN# 2,378,943 SN# 10-2002-7001095 SN# 00813372.7 SN# PA/a/2002/000938 SN# 00953666.5 SN# PI0012748.5 SN# Unknown SN# 2001-511880	07/24/00 08/21/02 10/01/02 10/01/02 08/20/03 08/21/03 08/20/03 08/19/03 08/19/03 08/19/03

ADDENDUM TO UCC FINANCING STATEMENT
DEBTOR: ADVISYS, INC.

AVSI	Title	Country	Patent or Patent Application No.	Filing Date
0018	Method of and Apparatus for Cell Poration and Cell Fusion Using Radiofrequency Electrical Pulses	United States	Patent No. 4,822,470 Patent No. 4,970,154 Patent No. 5,304,486 SN# 95115195.0 Patent No. 2,739,978	10/09/87 08/30/88 07/19/90 10/05/88 10/05/88
		European Application (DIV)		
		Japan		
		Canada		
		German		
		France		
		Italy		
		Great Britain		
0019	Modified Pituitary Gland Development in Offspring from Expectant Mother Animals Treated with Growth Hormone Releasing Hormone Therapy	United States	SN# 10/359,919 SN# PCT/US03/03640	02/06/03 02/06/03
		Argentina	SN# P030100375	02/06/03
		Chile	SN# 0230/2003	02/06/03
		Malaysia	SN# PI2003041	02/06/03
		Thailand	SN# 079845	02/06/03
		Taiwan	SN# 92102453	02/06/03
0021	Plasmid Mediated Gene Supplementation and In Vivo Expression of the Poly L-Glutamate (PLG) System	United States	SN# 10/395,709	03/24/03
		Argentina	SN# P030101880	05/28/03
		Chile	SN# 1039/2003	05/26/03
		Malaysia	SN# PI 20031939	05/26/03

Schedule I - 5

ADDENDUM TO UCC FINANCING STATEMENT
DEBTOR: ADVISYS, INC.

AVSI	Title	Country	Patent or Patent Application No.	Filing Date
0023	Codon Optimized Synthetic Plasmids	Taiwan	SN# 92114086	05/23/03
		Thailand	SN# 082550	05/23/03
		WIPO	SN# US03/16541	05/23/03
		United States	SN# 10/619,939	07/15/03
		Argentina	SN# P030102543	07/15/03
		Chile	SN# 1432/2003	07/15/03
0024	Protease Resistant TI-Growth Hormone Releasing Hormone [This is a CIP of AVSI-17; Super Porcine Growth Hormone Releasing Hormone analog]	Malaysia	SN# PI 20032637	07/15/03
		Taiwan	SN# 92119326	07/15/03
		Thailand	SN# 083818	07/16/03
		PCT	SN# PCT/US03/21917	07/15/03
		United States	SN# 10/166,356	08/21/02
0025	Mutated Skeletal Actin Promoter	United States	Patent No. 5,374,544	01/15/92
0026	IGF-1 Expression System and Methods of Use	United States	SN# 09/861,101	05/18/01
		EP Application	SN# 97950737.3	12/01/97
		Canada Application	SN# 2,274,314	12/01/97
		Australia Application	SN# 53662/98	12/01/97
		Japan	SN# 525696/98	12/01/97
		Australia (Div.)	SN# 97157/01	12/10/01

Schedule I - 6

ADDENDUM TO UCC FINANCING STATEMENT
DEBTOR: ADVISYS, INC.

AVSI	Title	Country	Patent or Patent Application No.	Filing Date
0027	Synthetic Muscle Promoters With Activities Exceeding Naturally Occurring Regulatory Sequences in Cardiac Cells	United States	SN# 60/423,536	11/04/02
0030	Device and Methods for Biomaterial Production	United States	SN# 60/474,749	05/30/03
0033	Reducing Culling in Herd Animals Growth Hormone Releasing Hormone (GHRH)	United States	SN# 60/443,104	01/28/03
0034	Insulin-Like Growth Factor (IGF-I) Plasmid-Mediated Supplementation for Therapeutic Applications	United States	SN# 60/454,079	03/12/03
0036	Increasing Fertility Rates in Animals by Using Growth Hormone Releasing Hormone (GHRH)	United States	SN# 60/457,214	03/25/03
0037	Plasmid Mediated GHRH Supplementation for Renal Failures	United States	SN# 60/464,266	04/21/03
0038	Canine-Specific Growth Hormone Releasing Hormone	United States	SN# 60/492,427	08/04/03

Patent Licenses

License Agreement dated June 26, 2000 with Baylor College of Medicine and Valentis Inc.
License Agreement, as amended, dated May 28, 2002 with Baylor College of Medicine

SCHEDULE II TO SECURITY AGREEMENT

Trademarks and Trademark Licenses

1. Trademark—"ADViSYS"
2. Trademark Licenses--None